x

Posted 22 August, 2022

TITAN PHARMACEUTICALS INC appointed Mr. Lazar as new CEO

Nasdaq:TTNP appointed new Chief Executive Officer Mr. Lazar in a 8-K filed on 22 August, 2022.


  Mr. Lazar was previously appointed to serve as the Company's Interim Chairman of the Board and Chief Executive Officer on August 15, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of TITAN PHARMACEUTICALS INC
Health Care/Life Sciences • Pharmaceuticals
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
Market Cap
$5.76M
View Company Details
TITAN PHARMACEUTICALS INC by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On August 16, 2022, the Board of Titan Pharmaceuticals, Inc. (the "Company") appointed David E. Lazar as the Principal Executive Officer and Principal Financial Officer of the Company. Mr. Lazar was previously appointed to serve as the Company's Interim Chairman of the Board and Chief Executive Officer on August 15, 2022.


Mr. Lazar, age 32, has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed public companies through custodianship, since February 2018, and Activist Investing LLC, an actively managed investment fund, since March 2018. Previously, Mr. Lazar served as Managing Partner at Zenith Partners International Inc., a boutique consulting firm, from July 2012 to April 2018. Mr. Lazar replaces Dr. Marc Rubin as the Company's Principal Executive Officer.


There are no arrangements or understandings between Mr. Lazar and any other persons pursuant to which he was selected as Principal Executive Officer or Principal Financial Officer. There are no family relationships between Mr. Lazar and any director or executive officer of the Company, and he has no indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.